RecruitingNCT05774561

Role of Liquid Biopsies in HPV-associated Cancer Treatment Monitoring

Liquid Biopsies - a Possible Tool for Treatment Monitoring and Early Recurrence Detection in HPV-associated Diseases


Sponsor

The Institute of Molecular and Translational Medicine, Czech Republic

Enrollment

480 participants

Start Date

Jun 1, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

This trial will evaluate the possible benefits and the performance of liquid biopsies in HPV-associated cancer treatment monitoring. This study aims to find a combination of an adequately sensitive and specific sampling method and biomarkers for early risk stratification of disease recurrence.


Eligibility

Min Age: 18 YearsMax Age: 99 Years

Inclusion Criteria1

  • Women diagnosed with CC/HSIL. Men and women diagnosed with OPC. Patients must agree with study enrollment and must sign study informed consent.

Interventions

DIAGNOSTIC_TESTArm A - Diagnostic test: HPV detection in liquid biopsies

Patients will be asked to perform self-collection of gargle lavage samples. Oropharyngeal swabs, breath condensate, and blood samples will be taken by trained clinicians.

DIAGNOSTIC_TESTArm B - Diagnostic test: HPV detection in liquid biopsies

Patients will be asked to perform cervicovaginal self-sampling using Evalyn Brush. Blood samples will be taken by trained clinicians.


Locations(1)

University Hospital Olomouc

Olomouc, Czechia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05774561


Related Trials